(Q44212348)

30 November 2017

title

Seroprevalence of seven high-risk HPV types in The Netherlands (English)

1 reference

30 November 2017

0 references

0 references

5

Hester E de Melker

1 reference

30 November 2017

6

Chris J L M Meijer

1 reference

30 November 2017

Mirte Scherpenisse

1

1 reference

30 November 2017

Madelief Mollers

2

1 reference

30 November 2017

Rutger M Schepp

3

1 reference

30 November 2017

Hein J Boot

4

1 reference

30 November 2017

Guy A M Berbers

7

1 reference

30 November 2017

Fiona R M van der Klis

8

1 reference

30 November 2017

language of work or name

English

0 references

publication date

7 September 2012

1 reference

30 November 2017

1 reference

30 November 2017

volume

30

1 reference

30 November 2017

issue

47

1 reference

30 November 2017

page(s)

6686-6693

1 reference

Clinician's guide to human papillomavirus immunology: knowns and unknowns

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

The natural history of cervical HPV infection: unresolved issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

HPV - immune response to infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Prevalence of human papillomavirus antibodies in young female subjects in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Seroprevalence of 34 human papillomavirus types in the German general population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Stability over time of serum antibody levels to human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Determinants for HPV vaccine uptake in the Netherlands: A multilevel study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Age-specific HPV seroprevalence among young females in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Multiplexed serologic assay for nine anogenital human papillomavirus types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

A statistically defined endpoint titer determination method for immunoassays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Seroprevalence of human papillomavirus type 16 infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Prevalence of human papillomavirus antibodies in males and females in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Seroprevalence of human papillomavirus type 16 in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Current concepts on human papillomavirus infections in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

High risk genital papillomavirus infections are spread vertically

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Detection of human papillomavirus DNA on the fingers of patients with genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Human papillomavirus-related disease in men: not just a women's issue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.068

10.1016/J.VACCINE.2012.08.068

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference